



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No. 03-170-A)

In re Application of:
Aquino et al.

Serial No.: 10/829,106

Filed: April 21, 2004

For: Benzamide 2-Hydroxy-3-Diaminoalkanes

Before the Examiner:
Bernard I. Dentz

Art Unit: 1625

Confirmation No.: 3902

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Dear Sir:

In regard to the above identified application:

1. We are transmitting herewith the attached:
 - a. Response to the Restriction Requirement Mailed June 1, 2006: and
 - b. Return Receipt Postcard.
2. With respect to fees:
 X No fee is required
3. Please charge any additional fees or credit overpayment to Deposit Account No. **13-2490**.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 30, 2006.

Date: June 30, 2006

By:


Steven J. Sarussi
Reg. No. 32,784

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, IL 60606
(312) 913-0001

Certificate of Mailing

I hereby certify that this response is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450,

on June 30, 2006 (Date of Deposit)

6/30/06
Date

Name



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No. 03-170-A)

In re Application of:)	
Aquino et al.)	Before the Examiner:
)	Bernard I. Dentz
Serial No.: 10/829,106)	
)	Art Unit: 1625
Filed: April 21, 2004)	
)	
For: Benzamide 2-Hydroxy-3-)	Confirmation No.: 3902
Diaminoalkanes)	


RESPONSE TO THE RESTRICTION REQUIREMENT
MAILED JUNE 1, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Responsive to the Restriction Requirement mailed June 1, 2006, Applicants elect the species of Example 24 on page 78 of the application as filed.

The elected compound can be represented by the formula:



and is named in the specification as: N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(((1S)-7-neopentyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino}propyl)benzamide. The above formula and name are both found on page 78 of the specification.

In addition, Applicants elect the disease species Alzheimer's Disease.

As suggested by the Examiner, Applicants have amended the claims to a "manageable scope."

The Listing of Claims begin on page 3 of this paper.

Remarks begin on page 25 of this paper.